Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, ...

The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of ...

NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients. Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform. NVCR ...

The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...

A head patch device that delivers alternating electrical fields to the brain has been shown to significantly improve survival in newly diagnosed glioblastoma patients. Developed by Jersey, US-based ...

LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...